Total submissions: 2
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Labcorp Genetics |
RCV001957853 | SCV002210082 | uncertain significance | Imerslund-Grasbeck syndrome | 2021-11-17 | criteria provided, single submitter | clinical testing | In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance. Algorithms developed to predict the effect of missense changes on protein structure and function are either unavailable or do not agree on the potential impact of this missense change (SIFT: "Tolerated"; PolyPhen-2: "Possibly Damaging"; Align-GVGD: "Class C0"). This variant has not been reported in the literature in individuals affected with CUBN-related conditions. This variant is present in population databases (rs147373223, gnomAD 0.007%). This sequence change replaces histidine, which is basic and polar, with arginine, which is basic and polar, at codon 1434 of the CUBN protein (p.His1434Arg). |
Ambry Genetics | RCV002562152 | SCV003554258 | uncertain significance | Inborn genetic diseases | 2021-10-22 | criteria provided, single submitter | clinical testing | The c.4301A>G (p.H1434R) alteration is located in exon 29 (coding exon 29) of the CUBN gene. This alteration results from a A to G substitution at nucleotide position 4301, causing the histidine (H) at amino acid position 1434 to be replaced by an arginine (R). Based on insufficient or conflicting evidence, the clinical significance of this alteration remains unclear. |